Experience real-time quotes, in-depth charts, and analyst ratings

MARKET

RXRX

Recursion Pharmaceuticals, Inc.

NASDAQ

8.05

+0.24

+3.07%

Pre Market: 8.40 +0.35 +4.35% 07:03 07/26 EDT

OPEN

7.80

PREV CLOSE

7.81

HIGH

8.56

LOW

7.68

VOLUME

8.28K

TURNOVER

52 WEEK HIGH

16.75

52 WEEK LOW

4.970

MARKET CAP

2.16B

P/E (TTM)

-4.9737

25 Best Artificial Intelligence Stocks to Buy Right Now

Artificial intelligence is revolutionizing industries across the board. These 25 companies span the spectrum, providing investors with a diversified basket of AI-centric equities. Companies like Alphabet, Microsoft, and Nvidia are leading the charge in AI development. The best way to gain exposure to the AI market is to buy a basket of these 25 companies.

The Motley Fool · 1d ago

Weekly Report: what happened at RXRX last week (0715-0719)?

Weekly Report · 4d ago

3 Millionaire-Maker Artificial Intelligence (AI) Stocks

Artificial intelligence (AI) is looking like a once-in-a-generation opportunity for investors. Companies with purposeful, practical, and targeted solutions stand to benefit the most from the rise of AI. SoundHound AI and Recursion Pharmaceuticals are two companies positioned to capitalize on the next stage of AI's rise. The company is developing AI tools to aid in the development of new drugs.

The Motley Fool · 07/18 10:10

Weekly Report: what happened at RXRX last week (0708-0712)?

Weekly Report · 07/15 09:19

Is Recursion Pharmaceuticals Stock a Buy?

Recursion Pharmaceuticals is trying to integrate AI, machine learning, and biotechnology into its drug development process. The company's pipeline has four programs in phase 2 and one in phase 1. Recursion is one of a handful of biotechs looking to integrate these trends. But the company is still early in the game and has a long way to go.

The Motley Fool · 07/14 10:25

1 Reason to Buy Recursion Pharmaceuticals Stock and 2 Reasons to Sell

Recursion Pharmaceuticals is using artificial intelligence to speed up drug discovery and development. The company doesn't have a product on the market or in late-stage studies. Its AI algorithm is designed to test clinical compounds against a library of human genes. The biotech's stock looks too risky for most investors, but the company could be a winner.

The Motley Fool · 07/13 13:29

Bank of New York Mellon Posts Upbeat Earnings, Joins Archer Aviation, Rivian Automotive And Other Big Stocks Moving Higher On Friday

The Bank of New York Mellon Corporation reported better-than-expected quarterly financial results. The Nasdaq Composite index gained around 100 points on Friday. Lucid Group, Inc. Shares jumped 17% to $3.9850 after the company reported better than expected quarterly results. Shares of the bank of new York Mellon also rose.

Benzinga · 07/12 14:27

These Nvidia-Backed Artificial Intelligence (AI) Stocks Could Soar 73% to 89% Higher, According to Wall Street

Wall Street has high expectations for three potential rising stars of the AI world. Nvidia has invested in Nano-X Imaging, Recursion Pharmaceuticals, and Soundhound AI. These Nvidia-backed stocks could soar 73% to 89% higher, according to analysts. Nvidia is the world's leading supplier of graphics processing units for artificial intelligence.

The Motley Fool · 07/12 09:50

About RXRX

Recursion Pharmaceuticals, Inc. is a clinical-stage TechBio company decoding biology to industrialize drug discovery. Its Recursion Operating System (OS), a platform built across diverse technologies, enables the Company to map and navigate trillions of biological and chemical relationships within the Recursion Data Universe. The Company integrates physical and digital components as iterative loops of atoms and bits scaling wet lab biology and chemistry data organized into virtuous cycles with computational tools to rapidly translate in silico hypotheses into validated insights and novel chemistry. Its clinical programs include REC-994, REC-2282, REC-4881 and REC-3964. REC-994 is an orally bioavailable, superoxide scavenger small molecule being development for the treatment of symptomatic cerebral cavernous malformation (CCM). REC-2282 for the potential treatment of neurofibromatosis type 2. REC-3964 for the prevention of recurrent Clostridioides difficile infection.

Webull offers Recursion Pharmaceuticals Inc stock information, including NASDAQ: RXRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RXRX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RXRX stock methods without spending real money on the virtual paper trading platform.